
    
      This is a phase IB, open-label, non-randomized, dose-escalation study that will be conducted
      in sequential cohorts of patients. Three patients per each cohort are planned.

      Patients, with advanced or metastatic solid tumor previously treated with a non cumulative
      dose of doxorubicin (<300 mg/sqm in order to allow an adequate number of cycles) or
      chemotherapy naÃ¯ve will be enrolled.
    
  